Why Myriad Genetics (MYGN) Stock Is Down Today

Myriad Genetics' stock plummets by nearly 20% following Q3 earnings report, as investors react to a lowered full-year earnings forecast, pushing shares down over 50% since January.The Daily News Now! — Every city. Every story. AI-powered. Hosted on Acast. See acast.com/privacy for more information.